NLS Pharma's ADHD drug sees success in mid-stage study.
M2 PHARMA-May 31, 2017-NLS Pharma's ADHD drug sees success in mid-stage study
(C)2017 M2 COMMUNICATIONS
Data from NLS Pharma AG's mid-stage trial for its drug mazindol to treat attention deficit hyperactivity disorder (ADHD) showed it greatly reduced symptoms in adult patients, Reuters reported on Wednesday.
Currently, stimulants and non-stimulants are the two types of approved treatments used to manage symptoms of ADHD, a chronic condition characterised by hyperactivity, impulse behaviour and a difficulty in maintaining focus.
The Swiss biotech's drug is a non-stimulant, however trial data revealed it could be as effective as a stimulant. These are generally more effective but have a risk to be abused and can be poorly tolerated by patients and, in rare cases, can even be fatal.
The trial involved 85 patients and the data showed that over half of the participants who received mazindol saw a reduction in ADHD symptoms of more than 50%, compared with a reduction of 15.8% in patients on placebo.
The company will now advance the drug onto a late-stage trial.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||May 31, 2017|
|Previous Article:||Roche Australia's Valium recalled following evidence of tampering.|
|Next Article:||MSD dispels fears for Ireland's future in pharma after Trump comments with EUR280m investment.|